Galy-Bernadoy Camille, Lallemant Benjamin, Chambon Guillaume, Pham Huy Trang, Reynaud Christophe, Alovisetti Caroline, Bonduelle Quentin, Guedj Anne Marie, Lumbroso Serge, De Brauwere David-Paul
Department of Oto-Rhino-Laryngology and Head and Neck Surgery, University Hospital of Nîmes, Nîmes, France.
Department of Endocrinology and Metabolic Diseases, University Hospital of Nîmes, Nîmes, France.
Eur Thyroid J. 2018 Jan;7(1):34-38. doi: 10.1159/000484689. Epub 2017 Dec 7.
Parathyroid hormone (PTH) is a risk marker for hypoparathyroidism (hypoPTH). This study aimed to determine the predictive values of early PTH assays carried out at the moment of skin closure (PTH SC), to establish a treatment algorithm, identifying two threshold values. We assessed the reproducibility of this approach with two different immunoassay kits (hypoPTH) after total thyroidectomy, but its practical application is not consensual.
We conducted a prospective descriptive study, including all patients who underwent a total thyroidectomy between March 2012 and November 2013. Postoperative PTH SC levels, corrected calcium on postoperative days, and occurrence of hypoPTH symptoms were collected.
Of 257 patients, the rate of hypoPTH was 20%. Threshold values to obtain a 100% positive predictive value to identify patients for whom hypoPTH was absolutely certain were: PTH SC <7 ng/L for the Roche kit and PTH SC <4 ng/L for the Beckman-Coulter kit. Threshold values to obtain a 100% negative predictive value to identify patients for whom the absence of hypoPTH was absolutely certain were: PTH SC ≥19 ng/L for the Roche kit and PTH SC ≥9 ng/L the Beckman-Coulter kit.
A single serum PTH sampled at skin closure is a reliable test to predict hypoPTH after a total thyroidectomy. The use of a threshold based on a 100% negative predictive value enables patients with no risk of hypoPTH to be safely discharged within the first 24 h postoperatively without unnecessary calcium and vitamin treatment. This medication can be given promptly to patients at risk of hypoPTH to limit the occurrence of hypocalcaemia.
甲状旁腺激素(PTH)是甲状旁腺功能减退症(甲状旁腺功能减退)的一个风险标志物。本研究旨在确定在皮肤缝合时进行的早期PTH检测(PTH SC)的预测价值,建立一种治疗算法,确定两个阈值。我们评估了在全甲状腺切除术后使用两种不同免疫分析试剂盒(甲状旁腺功能减退)时这种方法的可重复性,但其实际应用尚未达成共识。
我们进行了一项前瞻性描述性研究,纳入了2012年3月至2013年11月期间接受全甲状腺切除术的所有患者。收集术后PTH SC水平、术后各天的校正钙水平以及甲状旁腺功能减退症状的发生情况。
在257例患者中,甲状旁腺功能减退的发生率为20%。获得100%阳性预测值以确定甲状旁腺功能减退绝对确定的患者的阈值为:罗氏试剂盒的PTH SC<7 ng/L,贝克曼库尔特试剂盒的PTH SC<4 ng/L。获得100%阴性预测值以确定甲状旁腺功能减退绝对不存在的患者的阈值为:罗氏试剂盒的PTH SC≥19 ng/L,贝克曼库尔特试剂盒的PTH SC≥9 ng/L。
在皮肤缝合时采集的单次血清PTH是预测全甲状腺切除术后甲状旁腺功能减退的可靠检测方法。使用基于100%阴性预测值的阈值可使无甲状旁腺功能减退风险的患者在术后24小时内安全出院,无需进行不必要的钙和维生素治疗。对于有甲状旁腺功能减退风险的患者,可及时给予这种药物以减少低钙血症的发生。